Latest Breaking News On - Prnewswire inhibrx inc - Page 1 : comparemela.com

Inhibrx, Inc Announces Updated When-Issued Trading Date for Anticipated Spin-Off

Inhibrx, Inc Announces Updated When-Issued Trading Date for Anticipated Spin-Off
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Brendan eckelmanPrnewswire inhibrx incExchange commissionInhibrx incSecurities exchangeCompany annual report on formInhibrx biosciences incCompany onParty transactionsCompany definitive proxy statementInhibrx biosciencesNasdaq global marketEastern timeDefinitive proxy statementMiddle eastAnnual report

Inhibrx, Inc Announces Updated When-Issued Trading Date for Anticipated Spin-Off

Inhibrx, Inc Announces Updated When-Issued Trading Date for Anticipated Spin-Off
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Brendan eckelmanCompany annual report on formSecurities exchangeExchange commissionPrnewswire inhibrx incInhibrx incCompany definitive proxy statementParty transactionsCompany onInhibrx biosciences incInhibrx biosciencesNasdaq global marketEastern timeDefinitive proxy statementMiddle eastAnnual report

Inhibrx, Inc Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

Inhibrx, Inc Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Brendan eckelmanPrnewswire inhibrx incCompany onCompany definitive proxy statementParty transactionsCompany annual report on formExchange commissionSecurities exchangeInhibrx incInhibrx biosciences incAnnounces record dateExpected distribution timeAnticipated spin offExpected merger effective timeInhibrx biosciencesEastern time

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

/PRNewswire/ Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with three clinical programs in development and a strong.

Jon faiz kayyemKimberly manhardDouglas forsythSecurities exchangeAventis incInhibrx incParty transactionsCompany onInhibrx biosciences incPrnewswire inhibrx incExchange commissionInhibrx biosciencesNew inhibrxCompany employeesCurrently subjectCompany wide blackout restricting

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2 2B

Inhibrx, Inc. shareholders will receive per share consideration of $30 per share in cash, a CVR equal to $5, plus 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101.

United statesKayyem jon faizManhard kimberlyForsyth douglasGotshal mangesInhibrx biosciences incSecurities exchangePrnewswire inhibrx incCenterview partnersExchange commissionCompany onParty transactionsInhibrx incAventis incNew inhibrxInhibrx biosciences